Blood Cancer Journal (Jan 2023)
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
- Utkarsh Goel,
- Charalampos Charalampous,
- Prashant Kapoor,
- Moritz Binder,
- Francis K. Buadi,
- David Dingli,
- Angela Dispenzieri,
- Amie Fonder,
- Morie A. Gertz,
- Wilson I. Gonsalves,
- Suzanne R. Hayman,
- Miriam A. Hobbs,
- Yi L. Hwa,
- Taxiarchis Kourelis,
- Martha Q. Lacy,
- Nelson Leung,
- Yi Lin,
- Rahma M. Warsame,
- Robert A. Kyle,
- S. Vincent Rajkumar,
- Shaji K. Kumar
Affiliations
- Utkarsh Goel
- Division of Hematology, Mayo Clinic
- Charalampos Charalampous
- Division of Hematology, Mayo Clinic
- Prashant Kapoor
- Division of Hematology, Mayo Clinic
- Moritz Binder
- Division of Hematology, Mayo Clinic
- Francis K. Buadi
- Division of Hematology, Mayo Clinic
- David Dingli
- Division of Hematology, Mayo Clinic
- Angela Dispenzieri
- Division of Hematology, Mayo Clinic
- Amie Fonder
- Division of Hematology, Mayo Clinic
- Morie A. Gertz
- Division of Hematology, Mayo Clinic
- Wilson I. Gonsalves
- Division of Hematology, Mayo Clinic
- Suzanne R. Hayman
- Division of Hematology, Mayo Clinic
- Miriam A. Hobbs
- Division of Hematology, Mayo Clinic
- Yi L. Hwa
- Division of Hematology, Mayo Clinic
- Taxiarchis Kourelis
- Division of Hematology, Mayo Clinic
- Martha Q. Lacy
- Division of Hematology, Mayo Clinic
- Nelson Leung
- Division of Hematology, Mayo Clinic
- Yi Lin
- Division of Hematology, Mayo Clinic
- Rahma M. Warsame
- Division of Hematology, Mayo Clinic
- Robert A. Kyle
- Division of Hematology, Mayo Clinic
- S. Vincent Rajkumar
- Division of Hematology, Mayo Clinic
- Shaji K. Kumar
- Division of Hematology, Mayo Clinic
- DOI
- https://doi.org/10.1038/s41408-023-00785-y
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 4
Abstract
No abstracts available.
